Sanofi, ScionxBio to Develop Long-Acting xRNA Therapeutics

MT newswire2026/10/20 14:29

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10:29 AM EDT, 10/20/2026 (MT Newswires) -- Sanofi (SNY) struck a collaboration and licensing agreement with ScionxBio to develop long-acting xRNA therapeutics by leveraging the latter's TERA platform, ScionxBio said Tuesday. ScionxBio said it will lead activities up to in vivo validation stages, and Sanofi will then assume responsibility for remaining preclinical activities, studies, clinical development, manufacturing, and worldwide commercialization. The company said the programs are focused on conditions where sustained protein expression is important for clinical effects. Price: 40.66, Change: +1.09, Percent Change: +2.75

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

华尔街见闻•2026/11/08 12:41